Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intraumbilical Vein Injection of Oxytocin in Routine Practice for Active Management of the Third Stage of Labor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01094028
Recruitment Status : Completed
First Posted : March 26, 2010
Last Update Posted : March 26, 2010
Sponsor:
Information provided by:
Erzincan Military Hospital

Brief Summary:

During the first hours that follow the birth of the baby (third and fourth stages of labor), complications are common and can threaten the mother's life. The most common complication is postpartum hemorrhage (PPH), which remains a leading cause of maternal mortality (25.0%) especially in developing countries .Three to five percent of deliveries are complicated by PPH and is 50 times more common in developing countries. Retained placenta is an another complication of third stage of labor. It complicates 0.1-2 % of deliveries . Without prompt treatment, women are at high risk of hemorrhage. At present, treatment is by manual removal of placenta, which needs an operating theatre, a surgeon, and an anaesthetist—facilities that are often unavailable to women in resource-poor settings. As a result, this condition has a case fatality rate of nearly 10% in rural communities.

The length of the third stage of labor, and its subsequent complications depends on a combination of the length of time it takes for placental separation and the ability of the uterine muscle to contract. Principal management of the third stage of labor is aimed at reducing the time of delivery of placenta so minimising serious adverse effects, such as blood loss and retained placenta. Active management of the third stage of labor, which includes prophylactic injection of 10 units of oxytocin within two minutes of birth, early clamping of the umbilical cord and controlled cord traction (CCT), is recommended by WHO for PPH prevention .

Umbilical vein oxytocin injection directs the treatment to the placental bed and uterine wall, resulting in an earlier uterine contraction and placental separation. However, very limited published literature is available, which evaluated the effect of umbilical vein oxytocin injection in routine practices for active management of the third stage of labor. The purpose of this investigation was to find out the beneficial effect of adding intraumbilical vein oxytocin in reducing the blood loss during third and fourth stages of labor, length of third stage of labor, and reduction in the incidence of manual removal of retained placenta.


Condition or disease Intervention/treatment Phase
Labor Drug: Oxytocin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 412 participants
Allocation: Randomized
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Study Start Date : December 2009
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Oxytocin

Arm Intervention/treatment
Experimental: Saline group
Only 30 mL of saline was injected directly in the umbilical vein after clamping. The injection was performed with a 30-mL syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute and at the end of the injection, the solution was milked toward the cord insertion.
Drug: Oxytocin
20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion




Primary Outcome Measures :
  1. the amount of blood loss in third and fourth stages of labor [ Time Frame: The end of the delivery to 2 hours after birth. ]

Secondary Outcome Measures :
  1. duration of the third stage
    The duration of the third stage of labor was defined as the time difference (in minutes) between delivery of the infant and delivery of the placenta. The time interval was measured by the nurse attending the delivery and confirmed by the physician using a digital stop clock. The clock was started as soon as baby's body was totally delivered and stopped as soon as the placenta was completely expulsed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • gestational age between 37 and 42 weeks
  • singleton pregnancy
  • live fetus
  • cephalic presentation
  • neonatal birth weight of 2500-4500 g
  • parity between one and five
  • maternal age < 35 years
  • vaginal birth

Exclusion Criteria:

  • blood pressure ≥ 140/90mmHg
  • placenta previa
  • placental abruption
  • a history of any bleeding during pregnancy
  • a history of curettage
  • cesarean section or any uterine scar
  • a history of postpartum hemorrhage
  • polyhydramnios
  • signs or symptoms of maternal infection
  • known uterine anomalies
  • history of any drug use during labor
  • abnormal placentation)
  • coagulation defects
  • instrumental deliveries
  • hemoglobin concentration < 8 g/dL
  • history of anticoagulant drugs
  • beta-mimetic medications during pregnancy
  • prolongation of the first stage of labor > 15 hours.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: No sponsor
ClinicalTrials.gov Identifier: NCT01094028     History of Changes
Other Study ID Numbers: 07
First Posted: March 26, 2010    Key Record Dates
Last Update Posted: March 26, 2010
Last Verified: December 2009

Keywords provided by Erzincan Military Hospital:
Blood loss in the third and fourth stage of labor and the duration of third stage of labor

Additional relevant MeSH terms:
Layout table for MeSH terms
Oxytocin
Oxytocics
Reproductive Control Agents
Physiological Effects of Drugs